In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amersham's Push for High-Value Diagnostics

Executive Summary

Amersham Health is applying Big Pharma marketing and R&D strategies to the traditionally stodgy, highly price-sensitive field of diagnostic imaging contrast agents. It has been far more aggressive than competitors in working to make innovation the basis of competition. But some analysts question whether the company can maintain near-to-mid-term growth as it awaits results of its risky, long-term effort in molecular imaging.
Advertisement

Related Content

GE Acquires Clarient To Anchor Its Molecular IVD Business
The Pace of Development of Molecular Imaging Agents
GE'S Perception of Convergence
GE's Personalized Play for Amersham
Preparing Molecular Imaging's Future
Imaging in its Heyday: Clinical Applications (Part II)
Imaging in its Heyday: Research Applications (Part 1)
GE Medical and Amersham Sharpen Their Molecular Image
BioSite's Play for High-Value Diagnostics
The Contrast Media Wars Get Hot

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel